Heart Failure

 
Kidney Outcomes with Tirzepatide in T2D: Hiddo Heerspink, PhD, PharmD Highlights SURPASS-4 Analysis
June 06, 2022

ADA 2022: Professor Hiddo Heerspink led the prespecified SURPASS-4 analysis that found tirzepatide associated with a 41% reduction in risk of a composite renal outcome.

Empagliflozin More Effective to Reduce Risk of Heart Failure Hospitalization vs DPP-4 Inhibitors, GLP-1 Receptor Agonists
June 06, 2022

ADA 2022: In a real-world study of nearly half a million adults with T2D followed for 5 years, the SGLT-2 inhibitor surpassed both other classes used in routine clinical care.

Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
May 25, 2022

Kosiborod, a cardiologist, and Skolnik, a family practitioner, agree no single specialty owns that prescription and that "it takes a village to care for a patient."

Metformin, Lifestyle in Prediabetes May Reduce Risk of T2D but Not Major CV Events
May 24, 2022

Among more than 3000 participants with prediabetes, neither metformin or lifestyle change reduced risk for CV events over 21 years according to Diabetes Prevention Program Outcomes Study investigators.

SGLT-2 Inhibitors Belong to Patients, Not a Specialty or Primary Care: Experts Discuss
May 18, 2022

Mikhail Kosiborod, MD, a cardiologist and Neil Skolnik, MD, a primary care physician, agree that whoever is seeing the patient should prescribe the drug that is needed.

Dapagliflozin Now Poised to Treat HF Across Full Spectrum of Disease: DELIVER Phase 3 Top Line Findings
May 05, 2022

High-level results show the trial met its composite primary endpoint, lowering risk of CV death or worsening disease in patients with HFmrEF/HFpEF.

SGLT-2 Inhibitor and GLP-1 Receptor Agonist Prescribing Trends 2015-2020
May 04, 2022

PCPs and internists accounted nationally for 57% of SGLT2i and 52% of GLP1RA prescriptions in 2020, more than any other specialty, according to new research.

FDA Approves Mavacamten, First-in-Class Treatment for Obstructive Hypertrophic Cardiomyopathy
May 02, 2022

The cardiac myosin inhibitor is the only treatment that targets the pathophysiology of the disease, improving patient function and symptoms.

Smoking Cessation as Effective as 3 Meds in Secondary CVD Prevention: 5 Event-free Years
April 13, 2022

Persons with ASCVD who quit smoking could gain 5 more years of life--similar to the outcome of intensive medical treatment while continuing to smoke.

Finerenone Consistently Reduced Cardiorenal Risk Regardless of ASCVD History in FIDELITY
April 08, 2022

In patients with type 2 diabetes and chronic kidney disease with and without history of CVD, finerenone was associated with improved CV and kidney outcomes.